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Although the skeleton is a common site of metastasis for
many solid tumours, metastatic bone disease is particularly
relevant in prostate and breast cancers. Thus, bone is the
most frequent – and often the only – location of metastasis
in patients with advanced prostate cancer. Moreover, up to
70% of patients with metastatic breast cancer develop bone
metastases over the course of their disease.
Metastatic bone involvement usually results in multiple
skeletal complications leading to a significant deterioration
in the quality of life for cancer patients. Pain, hypercalcemia
and skeletal-related events (SREs) – such as the use of
radiotherapy or surgery of bone, pathological fractures and
spinal cord compression – are problems typically derived
from bone metastases [1].
The pathogenesis of bone metastases is a complex process
involving many interactions between tumour cells and osteo-
clasts and osteoblasts. Receptor activator of nuclear factor-jb
(RANK) ligand (RANKL), which is expressed by osteoblasts and
marrow stromal cells, is a potent inducer of osteoclast forma-
tion. In bone metastases, cytokines and growth factors
secreted by tumour cells (interleukins 1 and 6, parathyroid-
hormone-related peptide, tumour necrosis factor, prostaglan-
din E2, and macrophage-colony-stimulating factor, amongst
others) increase the expression of RANKL on marrow stromal
cells and osteoblasts [2]. Following this, RANKL binds to its
receptor, RANK, on the surface of osteoclast precursors and
stimulates the differentiation of these cells to mature osteo-
clasts. This excessive RANKL-induced osteoclast activity
results in increased bone resorption and local bone destruc-
tion, leading to the release of growth factors from the bone
matrix that subsequently promotes tumour progression. This
relationship between tumour and bone cells constitutes the
vicious cycle of bone metastases.
For all these reasons, patients with metastatic bone
involvement who show higher levels of bone turnover mark-ers have a particularly high risk for SREs in addition to worse
clinical outcomes [3].
Treatment of bone metastases requires a broad strategy
with different therapeutic options, including both local and
systemic therapies. External-beam radiotherapy remains the
mainstay of treatment for symptomatic bone metastases.
However, considering that osteoclast-mediated bone resorp-
tion plays a critical role in the development of metastatic
bone disease, its inhibition represents an attractive target
for treating bone metastases. Below, some of the major man-
agement approaches are very briefly summarised.
2. Bisphosphonates
Bisphosphonates are chemically stable derivatives of inor-
ganic pyrophosphate. These compounds are potent inhibitors
of osteoclast-mediated bone resorption through two
well-recognised mechanisms of action. On the one hand,
first-generation non-nitrogen-containing bisphosphonates
(i.e. clodronate) are metabolised by osteoclasts to cytotoxic
ATP analogues; on the other hand, second- and third-genera-
tion nitrogen-containing bisphosphonates, such as zoledron-
ic acid and pamidronate, act by inhibiting farnesyl
diphosphate synthase, a key enzyme of the mevalonate
pathway.
Over the last two decades these agents – in particular
zoledronic acid and pamidronate – have been the most effec-
tive treatments in delaying or preventing SREs in patients
with bone metastases from solid tumours, as well as in pa-
tients with multiple myeloma [4].
3. Denosumab
Denosumab is a fully human monoclonal antibody that binds
to RANKL in order to inhibit osteoclast activity. Denosumab
has been evaluated in three identically designed, randomised,
double-bind, phase III clinical trials [5–7]. Patients were
Table 1 – Phase III studies with denosumab in patients with bone metastases or myeloma multiple.
Number of patients Type of tumour Time to first
on-study SRE
Overall
survival
Time to disease
progression
Refs.
1904 Prostate cancer HR = 0.82 (P = 0.0002
for non-inferiority analysis;
P = 0.008 for superiority analysis)
HR = 1.03
(P = 0.65)
HR = 1.06(P = 0.3) [5]
1776 Myeloma multiple;
solid tumours
(except breast and prostate)
HR = 0.84 (P = 0.0007 for
non-inferiority analysis)
HR = 0.95
(P = 0.43)
HR = 1(P = 1) [6]
2046 Breast cancer HR = 0.82 (P < 0.001 for
non-inferiority analysis;
P = 0.01 for superiority analysis)
HR = 0.95
(P = 0.49)
HR = 1(P = 0.93) [7]
SRE, skeletal-related event; HR, hazard ratio.
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mab 120 mg and intravenous placebo or intravenous zoled-
ronic acid 4 mg and subcutaneous placebo every 4 weeks.
The primary endpoint was time to first on-study SRE (defined
as pathological fractures, the use of radiotherapy or surgery of
bone, or spinal cord compression). These studies are summa-
rised in Table 1.
Overall, adverse events and serious adverse events were
similar with both treatments, although more acute-phase
reactions and renal adverse events occurred in the zoledronic
acid group, whereas hypocalcemia was more frequent with
denosumab. Additionally, the rate of osteonecrosis of the
jaw was low in both arms (2%).
4. Other agents
4.1. Mammalian target of rapamycin (mTOR) inhibitors
mTOR inhibition decreases osteoclast maturation and in-
creases osteoclast apoptosis, resulting in reduced bone
resorption in animal models [8].
In the randomised phase III trial with everolimus in meta-
static breast cancer (BOLERO-2), a total of 724 postmeno-
pausal women with oestrogen-receptor-positive breast
cancer refractory to non-steroidal aromatase inhibitor ther-
apy were treated with exemestane and randomised (2:1) to
everolimus or placebo. The addition of everolimus signifi-
cantly improved median progression-free survival, the pri-
mary endpoint of this study (6.9 months versus 2.8 months;
HR = 0.43; P < 0.001) [9]. An exploratory endpoint also included
the evaluation of changes in bone turnover marker levels and
the rate of progressive disease in bone, defined as unequivo-
cal progression of a pre-existing bone lesion or the appear-
ance of a new bone lesion [10]. Everolimus added to
exemestane significantly decreased bone turnover marker
levels at 6 and 12 weeks. Moreover, the cumulative incidence
rate of progressive disease in bone was lower in the combina-
tion arm.
5. Novel compounds
Other bone-targeting agents are currently under investiga-
tion, although the clinical development of SRC- and C-MET
inhibitors is further along. Both have shown importantbone-specific activity in patients with breast or prostate can-
cer, as well as in preclinical models [11,12].
6. Conclusions
A better understanding of the biology of bone metastases is
establishing an exciting scenario in the treatment of this dis-
ease. This explosion of data has led to a large increase in
knowledge and the subsequent introduction of new bone-tar-
geted therapies in daily practice.Conflict of interest statement
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